Global Mycoplasma Testing in Clinical Market – Industry Trends and Forecast to 2030

Mycoplasma Testing in Clinical Market Analysis and Size

According to the CDC, the number of deaths from chronic lower respiratory diseases will be 152,657 in 2021. The number of deaths from respiratory illnesses, pulmonary disease, and tuberculosis has increased, and these figures are expected to rise further in the coming years, fueling the growth of the mycoplasma testing in clinical market. Furthermore, key market participants anticipate an increase in demand for improved diagnostics for non-pulmonary therapies, which will drive the global market in the near future.

Data Bridge Market Research analyses that the mycoplasma testing in clinical market which was USD 295.06 million in 2022, is expected to reach USD 526.23 million by 2030, at a CAGR of 7.5% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Mycoplasma Testing in Clinical Market Scope and Segmentation  

Market Definition

A mycoplasma test is used to identify an active or recent mycoplasma infection, which is a type of bacterial infection. Testing may be done in a variety of ways depending on which one is suspected, because there are different types of mycoplasma infections. The most common Mycoplasma is M. pneumoniae, which causes upper respiratory infections and can be tested with a blood sample. Other mycoplasma tests, may necessitate the collection of various types of samples, such as sputum, joint fluid, body fluids, tissue samples, or a genital swab.

Mycoplasma Testing in Clinical Market Dynamics

Drivers

• Increasing R&D investments

Rising research costs and increasing R&D investments by key companies will likely encourage firms to adopt highly efficient mycoplasma testing tools. For instance, Bristol-Myers Squibb began investing in developing investigational medicines to support clinical trials. Furthermore, with the introduction of biosimilar and the resulting lucrative R&D investment, it has become critical to conduct safety testing to ensure that a product meets the standards for efficacy, safety, and overall public health. Merck KGaA expanded its manufacturing footprint in the United States in December 2020, investing more than USD 45.6 million (EUR 40 million) in its Massachusetts and New Hampshire production facilities. The sites were designed to produce a variety of biopharmaceutical manufacturing products while also increasing the company's production capacity. This is expected to further improve the penetration of mycoplasma testing tools.

• Growing concerns over cell culture contamination

The most common problem in cell culture laboratories is contamination. Cell culture contaminations are classified into two types: chemical contamination and biological contamination. Impurities, sera, water, and endotoxins are among the chemical contaminants. Various tests, including mycoplasma testing, are also used to detect contamination.

Opportunities

• Globalization of clinical trials

The primary reasons pharmaceutical and biopharmaceutical companies choose to outsource clinical trials and R&D are cost efficiency, ease of patient recruitment, lower operating costs, and less stringent regulatory frameworks than those found in the United States and Western Europe. Aside from cost savings, sponsors cite improved quality and reduced time to market as key reasons for outsourcing business functions to CROs, CDMOs, and CMOs.

Restraints/Challenges

• High cost of instruments

The high cost of instruments, as well as the lengthy and laborious detection process, are expected to limit the growth of the mycoplasma testing in clinical market during the forecast period.

This mycoplasma testing in clinical market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the mycoplasma testing in clinical market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In 2020, Liofilchem S.r.l launched the AF Genital System, VTM, Lockable contact plates with the improved configuration used for microbial testing. This product improvement assisted the company in increasing its revenue.
• In 2020, BioMérieux SA announced the launch of the biofire mycoplasma test for mycoplasma detection in biopharmaceutical products. This initiative aided the company in expanding its product usage in the biotherapeutics market.

Global Mycoplasma Testing in Clinical Market Scope

The mycoplasma testing in clinical market is segmented on the basis of products, technique, application, disease area and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Products

• Kits and Reagents
• Instruments
• Services

 Technique

• Microbial Culture Techniques/Direct Assay
• Polymerase Chain Reaction
• ELISA
• DNA Staining/Indirect Assay
• Enzymatic Methods

 Application

• Cell Line Testing
• Virus Testing

 Disease Area

• Respiratory
• Urogenital
• Gastrointestinal
• Musculoskeletal
• Cardiovascular
• Others

 End User

• Diagnostic Laboratories
• Hospitals

Mycoplasma Testing in Clinical Market Regional Analysis/Insights

The mycoplasma testing in clinical market is analyzed and market size insights and trends are provided by country, products, technique, application disease area and end user as referenced above.

The countries covered in the mycoplasma testing in clinical market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the mycoplasma testing in clinical market because of repeated purchases of consumables for the detection of mycoplasma in cell culture, the kits and reagents segment is expected to grow at the fastest rate as well.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 owing to increased demand for effective testing, the kits and reagents segment in Germany is dominating the mycoplasma testing in clinical market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The mycoplasma testing in clinical market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for mycoplasma testing in clinical market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the mycoplasma testing in clinical market. The data is available for historic period 2011-2021.

Competitive Landscape and Mycoplasma Testing in Clinical Market Share Analysis

The mycoplasma testing in clinical market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to mycoplasma testing in clinical market.

Some of the major players operating in the mycoplasma testing in clinical market are:

• AB ANALITICA s.r.l. (Italy)
• BIOMÉRIEUX (France)
• ELITechGroup (France)
• Liofilchem S.r.l. (Italy)
• Agilent Technologies, Inc. (U.S.)
• PromoCell GmbH (Germany)
• F. Hoffmann-La Roche Ltd (Switzerland)
• OSANG Healthcare (South Korea)
• Sacace Biotechnologies Srl (Italy)
• Lonza (Switzerland)
• Merck KGaA (Germany)
• Seegene Inc. (South Korea)
• Clongen Laboratories, LLC (U.S.)
• Bio-Rad Laboratories, Inc. (U.S.)
• Charles River Laboratories (U.S.)
• Bionique Testing Laboratories LLC (U.S.)
• ZEAKON Diagnostics (India)

SKU-44726